Topiramate Capsule
Product Images NDC 51407-894

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 51407-894). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-893-60ol (Topiramate 15 mg)

51407-893-60ol (Topiramate 15 mg)
Topiramate 15 mg capsules, USP label from Golden State Medical Supply, Inc. The label indicates a package of 60 capsules with a white to off-white spherical coated pellet inside a white opaque capsule body marked as '15 mg' and a clear cap marked 'TWi T210'. It includes storage instructions and pharmacist dispensing information with a National Drug Code (NDC) of 51407-893-60.*
FDA Label Image

51407-894-60ol (Topiramate 25 mg)

51407-894-60ol (Topiramate 25 mg)
Topiramate 25 mg capsules, USP, oral prescription medication labeled by Golden State Medical Supply, Inc. The bottle contains 60 capsules. The label features dosage information, storage instructions, and a barcode. Capsules have white opaque bodies with clear caps, marked with strength and identification codes.*
FDA Label Image

Figure1 (Figure 1)

Figure1 (Figure 1)
A line graph showing cumulative rates for time to first seizure over 500 days. Two groups are compared: Topamax 50 mg/day (solid line) and Topamax 400 mg/day (dashed line), with respective sample sizes noted. The graph includes a p-value of 0.0002, indicating statistical analysis of differences between groups.*
FDA Label Image

Figure2 (Figure 2)

Figure2 (Figure 2)
A bar chart comparing the change from baseline to double-blind phase in average monthly migraine period rate for placebo and different Topamax dosages (50 mg/day, 100 mg/day, 200 mg/day) across two studies. The chart shows a decrease in migraine period rate with increasing Topamax dose, with statistical significance indicated for the 100 mg/day and 200 mg/day doses.*
FDA Label Image

Logo (Logo 2)

FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure diagram of the active ingredient Topiramate showing its molecular components and bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.